NASDAQ$YMAB
Y-mAbs Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021.
Y-mAbs reported net revenues of $11.0 million for the quarter ended June 30, 2021, consisting of $9.0 million of DANYELZA revenues and $2.0 million of licensing revenue. The company ended the quarter with a cash balance of $233.6 million.
- DANYELZA commercialization is progressing throughout the U.S.
- DANYELZA BLA submission accepted by the National Medical Products Administration of China.
- Submitted the European Marketing Authorization Application to the European Medicines Agency for omburtamab in April.
- Awaiting positive Type B meeting with the FDA in the third quarter to initiate rolling resubmission of the omburtamab BLA by the end of the year.
Headline financials
Revenue & EPS history
Y-mAbs · Revenue · Quarterly
$11M
Forward guidance
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
-5.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+54.6%
Q4 2022
Best reaction
-21.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | +0.0% | +0.8% | |
| Q1 2025 | -11.4% | +0.2% | +14.0% | |
| Q4 2024 | -4.4% | -0.4% | -9.9% | |
| Q3 2024 | -4.4% | -15.2% | -32.3% | |
| Q2 2024 | -3.5% | +9.4% | +18.4% | |
| Q1 2024 | -21.1% | -25.4% | -28.7% | |
| Q4 2023 | +14.5% | +2.0% | -0.2% | |
| Q3 2023 | +6.1% | — | — | |
| Q2 2023 | -5.0% | — | — | |
| Q1 2023 | +33.6% | — | — | |
| Q4 2022 | +54.6% | — | — | |
| Q3 2022 | +15.4% | — | — | |
| Q2 2022 | -5.6% | — | — | |
| Q1 2022 | +13.2% | — | — | |
| Q4 2021 | +12.9% | — | — | |
| Q3 2021 | -19.7% | — | — | |
| Q2 2021 | -17.8% | — | — | |
| Q1 2021 | +20.8% | — | — | |
| Q4 2020 | -3.6% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -1.6% | — | — | |
| Q1 2020 | +14.4% | — | — | |
| Q4 2019 | -8.7% | — | — | |
| Q3 2019 | -1.6% | — | — | |
| Q2 2019 | +2.4% | — | — | |
| Q1 2019 | -9.9% | — | — | |
| Q4 2018 | -4.4% | — | — | |
| Q3 2018 | -1.1% | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro